Biomed-Lublin begins production of Covid immunoglobulin

In a bid to battle the coronavirus, Biomed-Lublin, a biotech company in eastern Poland, has started the process of producing immunoglobulin from the plasma of convalescents, the company has claimed in a press release.

The project is carried out as part of the Medical Research Agency (ABM) competition to minimize the epidemiological threat associated with the spread of the coronavirus.

“The manufacturing process will take about 1.5 months. And after the batch of the drug is manufactured by the issuer, it will be handed over to the remaining consortium members: the Institute of Hematology and Transfusion Medicine and the Public University Hospital No. 1 in Lublin in order to perform the necessary tests in accordance with the project schedule,” stated the firm.

At the end of July, the company informed that the Regional Blood Donation and Blood Treatment Centers (RCKiK) collected 171.7 liters of plasma containing coronavirus antibodies, the amount necessary to start the production of the preparation.

(PAP)